Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0435)
| Name |
SN38
|
||||
|---|---|---|---|---|---|
| Drug Type |
Small molecule
|
||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| In Vitro Model | Colon 26-L5 cells | Colon adenocarcinoma | Mus musculus | CVCL_3924 |
| Response regulation | The anticancer effect of the combined treatment of SN38 and EP is related to changes in the redox-homeostasis of cancer cells, leading to cell death via apoptosis and/or ferroptosis. Thus, electroporation has a potential to increase the sensitivity of colorectal cancer cells to conventional anticancer therapy with SN38. | |||